Solasia Pharma K.K. Stock Price

TSE:4597 Community·JP¥8.6b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

4597 Share Price Performance

JP¥32.00

-9.00 (-21.95%)

JP¥32.00

-9.00 (-21.95%)

JP¥32.00

Sat, 14 Mar 26

Share Pricen/a

4597 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

1 Reward

View Full Analysis

Solasia Pharma K.K. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -3.25
: 48.48%
: -204.20%
: 0%

View Full Analysis

About 4597

Founded: 2006
Employees: 23
CEO: Yoshihiro Arai
WebsiteView website: www.solasia.co.jp

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.